Background: Global vaccination against COVID-19 will help nations to overcome the pandemic stage as soon as possible. Guillain-Barré syndrome (GBS) is an acute immune-mediated inflammatory disease of the peripheral nerves (PNS) that is reported as a complication of both COVID-19 and vaccines. Up to now, case reports regarding the incidence of GBS have been reported after different COVID-19 vaccines worldwide. So, the aim of this systematic review and meta-analysis is to estimate the pooled incidence of GBS after COVID-19 vaccination.
Methods: Two expert researchers conducted a systematic search in PubMed, Scopus, EMBASE, Web of Science, Google Scholar as well as gray literature in order to find relevant articles published before September 2022.
Results: After deleting duplicates, we found 1021 articles, of which 458 studies were further evaluated. A final number of 21 studies remained for meta-analysis, with most of those being from the USA, UK and Mexico. Follow-up duration was between 21-42 days. Out of the total number of 2.35x109 patients included in the final meta-analysis, 3654 subjects developed GBS after vaccination, most of whom were males. Incidence of GBS per million ranged between 0.23 and 9.8. The pooled incidence of GBS following vaccination was 0%.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345054 | PMC |
http://dx.doi.org/10.26574/maedica.2024.19.2.410 | DOI Listing |
J Neurol
January 2025
Research, Diagnosis and Reference Center, PAHO/WHO Collaborating Center for the Study of Dengue and Its Control, Institute "Pedro Kourí", Havana, Cuba.
BMC Neurol
January 2025
Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
Background: Guillain-Barré syndrome (GBS) presents with progressive ascending weakness, but it can also present with dysautonomia such as tachycardia, blood pressure fluctuations, diaphoresis, ileus, and urinary retention. GBS patients with dysautonomia was observed to have longer hospital stays and higher mortality rates than those without dysautonomia. We aimed to determine the risk factors for dysautonomia and its manifestations among patients with GBS and compared their features to those without dysautonomia.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Obstetrics and Gynecology, Taixing People's Hospital, No.1, Changzheng Road, Taixing, Jiangsu, 225400, China.
Background: Group B Streptococcus (GBS) colonization is one of the major causes of severe neonatal infections. The study was intended to identify GBS colonization in pregnant women, explore its potential risk factors, and analyze the impact of GBS on outcomes for both mothers and newborns.
Material And Methods: A retrospective research was carried out on pregnant women who had undergone GBS screening and delivered from June 2020 to December 2022.
BMC Pediatr
January 2025
Department of Neonatology, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Background: Group B Streptococcus (GBS) is the most common cause of neonatal early onset sepsis in term infants and a major cause of late onset sepsis in both term and preterm infants.
Aim: To estimate the incidence of GBSS among neonates born in Qatar between July 2015 and June 2020 (5 years). A secondary aim was to describe the outcomes of the affected babies.
PeerJ
January 2025
Center of Reproductive Medicine, Qingdao Women and Children's Hospital, Qingdao, China.
Background: Group B streptococcus (GBS) colonization in pregnant women is associated with adverse perinatal outcomes, including stillbirth. This meta-analysis investigated the relationship between maternal rectovaginal GBS colonization and the risk of stillbirth.
Methods: We conducted a comprehensive literature search across several databases, including PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure, covering studies published from the inception of the database until September 9, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!